Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study

    May 2025 in “ Cureus ”
    Asem Aldebei, Yara S Hammouri, Salah Abdallat … Mohammad Luay Alkotob
    Studysummary This study assessed the effectiveness of JAK inhibitors in Jordanian patients with alopecia areata, finding that while both tofacitinib and baricitinib improved SALT scores, baricitinib showed greater improvement and a trend towards better hair regrowth, particularly with longer treatment durations.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on assets.cureus.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure Archives of Dermatological Research · 2025
    2. Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study Journal of Cosmetic Dermatology · 2024
    3. Past, Present, and Future Treatment of Alopecia Areata Medical & clinical research · 2024
    4. Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2024
    5. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    6. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    7. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    8. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    9. Alopecia Areata: Characteristics, Progression, and Associated Conditions Journal of vaccines and immunology · 2023
    10. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    11. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    12. Alopecia Areata: An Autoimmune Disease of Multiple Players ImmunoTargets and therapy · 2021
    13. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    14. Treatment of Pediatric Alopecia Areata: A Systematic Review Journal of the American Academy of Dermatology · 2021
    15. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    16. Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2015
    17. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014